A fatal case report of antibody-dependent enhancement of dengue virus type 1 following remote Zika virus infection

Dengue virus (DENV) is endemic in many parts of the world. Antibody dependent enhancement (ADE) in DENV infections occurs when a person with primary immunity is infected by a second, different DENV strain. Antibodies to Zika virus (ZIKV), which emerged in the Western Hemisphere in 2015, are cross re...

Full description

Saved in:
Bibliographic Details
Published in:BMC Infectious Diseases 2021, Vol.21 (1)
Main Authors: Bonheur, Ashley N, Thomas, Sarah, Soshnick, Sara H, McGibbon, Emily, Dupuis, Alan P, Hull, Rene, Slavinski, Sally, Del Rosso, Paula E, Weiss, Don, Hunt, Danielle T, McCabe, Megan E, Dean, Amy B, Folkerth, Rebecca, Laib, Anne M, Wong, Susan J
Format: Report
Language:English
Subjects:
Case studies
Dengue
Pediatric research
Risk factors
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Dengue virus (DENV) is endemic in many parts of the world. Antibody dependent enhancement (ADE) in DENV infections occurs when a person with primary immunity is infected by a second, different DENV strain. Antibodies to Zika virus (ZIKV), which emerged in the Western Hemisphere in 2015, are cross reactive with DENV and theoretically could provoke ADE in a DENV naïve individual. We report the first known patient in the United States with a rapidly progressive and fatal case of travel-associated DENV in which prior exposure to ZIKV likely played a role in triggering an ADE phenomenon. This association of prior ZIKV immunity and subsequent new dengue infection is a worrisome phenomenon and an important contribution to the body of knowledge on immunity to flaviviruses.
ISSN:1471-2334
1471-2334
DOI:10.1186/s12879-021-06482-0